<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089661</url>
  </required_header>
  <id_info>
    <org_study_id>20040135</org_study_id>
    <nct_id>NCT00089661</nct_id>
  </id_info>
  <brief_title>AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects
      undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Low Bone Mineral Density</condition>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>AMG 162 / Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 162 / Denosumab</intervention_name>
    <description>60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months</description>
    <arm_group_label>AMG 162 / Denosumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Histologically or cytologically confirmed adenocarcinoma of the breast

          -  Subjects with early stage disease who are estrogen receptor positive and who have
             completed their treatment pathway (surgery, chemo-therapy, radiation, and/or hormone
             therapy) and are currently on or will initiate aromatase inhibitor therapy, and are
             expected to stay on aromatase inhibitor therapy for the duration of the 24-month study

          -  All treatment pathway must be completed ≥ 4 weeks prior to study entry, and all acute
             toxic effect of any above therapy must be resolved to ≤ Grade 1 by National Cancer
             Institution (NCI) Common Terminology Criteria for Adverse Events (CTCAE)

          -  Female &gt; 18 years of age

          -  ECOG Performance status 0 and 1

          -  Lumbar spine, total hip or femoral neck BMD equivalent to a t-score classification of
             -1.0 to -2.5

          -  Subject is willing and able to provide signed consent before any study-specific
             procedure

        Other criteria also apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4875-82. doi: 10.1200/JCO.2008.16.3832. Epub 2008 Aug 25.</citation>
    <PMID>18725648</PMID>
  </results_reference>
  <results_reference>
    <citation>Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, Kim D. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009 Nov;118(1):81-7. doi: 10.1007/s10549-009-0352-y. Epub 2009 Mar 24.</citation>
    <PMID>19308727</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2004</study_first_submitted>
  <study_first_submitted_qc>August 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2004</study_first_posted>
  <results_first_submitted>December 22, 2009</results_first_submitted>
  <results_first_submitted_qc>December 22, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2010</results_first_posted>
  <disposition_first_submitted>November 19, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 19, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 23, 2009</disposition_first_posted>
  <last_update_submitted>July 23, 2013</last_update_submitted>
  <last_update_submitted_qc>July 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Bone loss associated with Aromatase Inhibitor therapy (AIT) for non-metastatic BC</keyword>
  <keyword>osteopenia</keyword>
  <keyword>Low bone density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Denosumab 60 mg Q6M</title>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligibility determined</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Denosumab 60 mg Q6M</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="252"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="8.9"/>
                    <measurement group_id="B2" value="59.7" spread="9.7"/>
                    <measurement group_id="B3" value="59.5" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>12 months</time_frame>
        <population>Subjects with non-missing baseline and &gt;= 1 non-missing post-baseline evaluation. Using Last Observation Carried Forward as imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 60 mg Q6M</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <population>Subjects with non-missing baseline and &gt;= 1 non-missing post-baseline evaluation. Using Last Observation Carried Forward as imputation.</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="4.3" upper_limit="5.4"/>
                    <measurement group_id="O2" value="-.7" lower_limit="-1.3" upper_limit="-.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.8</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 6</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 60 mg Q6M</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 6</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.2" upper_limit="4.2"/>
                    <measurement group_id="O2" value="-.6" lower_limit="-1.1" upper_limit="-.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 60 mg Q6M</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="2.6" upper_limit="3.5"/>
                    <measurement group_id="O2" value="-.7" lower_limit="-1.1" upper_limit="-.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 6</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 60 mg Q6M</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 6</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.9" upper_limit="2.8"/>
                    <measurement group_id="O2" value="-.4" lower_limit="-.8" upper_limit=".1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 60 mg Q6M</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.1" upper_limit="2.6"/>
                    <measurement group_id="O2" value="-.6" lower_limit="-1.4" upper_limit=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 6</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 60 mg Q6M</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 6</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit=".5" upper_limit="1.9"/>
                    <measurement group_id="O2" value="-.9" lower_limit="-1.6" upper_limit="-.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Denosumab 60 mg Q6M</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

